Clinical Cancer Research · 2004 · 67 citations · 48 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer BiomarkersCancer ImmunotherapyEsophageal CancerTumor AntigensTumor-associated AntigensCancer AntigensImmunohistochemical DetectionMicroarray AnalysisTissue Microarray AnalysisTumor Antigen DiscoveryTumor Antigen Expression ProfilingTumor Antigen IdentificationTumor Antigen-based Immunotherapy
PURPOSE: To establish effective antitumor immunotherapy for esophageal cancer, we tried to identify an useful target antigen of esophageal cancer. EXPERIMENTAL DESIGN: We did cDNA microarray analysis to find a novel candidate antigen, proliferation potential-related protein (PP-RP). We examined cytotoxicity against tumor cells in vitro and in vivo of CTLs specific to PP-RP established from esophageal cancer patients. RESULTS: In 26 esophageal cancer tissues, an average of relative ratio of the expression of the PP-RP mRNA in cancer cells versus adjacent normal esophageal tissues was 396.2. Immunohistochemical analysis revealed that, in 20 of the 22 esophageal cancer tissues, PP-RP protein was strongly expressed only in the cancer cells and not so in normal esophageal epithelial cells. PP-RP protein contains 10 epitopes recognized by HLA-A24-restricted CTLs. These CTLs, generated from HLA-A24-positive esophageal cancer patients, had cytotoxic activity against cancer cell lines positive for both PP-RP and HLA-A24. Furthermore, adoptive transfer of the PP-RP-specific CTL line inhibited the growth of a human esophageal cancer cell line engrafted in nude mice. CONCLUSIONS: The expression of PP-RP in esophageal cancer cells was significantly higher than in normal cells, and the CTLs recognizing PP-RP killed tumor cells in vitro and also showed tumor rejection effects in a xenograft model. Therefore, PP-RP may prove to be an ideal tumor antigen useful for diagnosis and immunotherapy for patients with esophageal cancer. cDNA microarray analysis is a useful method to identify ideal tumor-associated antigens.
48
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Frank O. Nestlé, Selma Alijagic, Michel Gilliet et al. · Nature Medicine · 1998 · 2.9K citations
Medicine, Immunology, Oncology +14
Elke Jäger, Yao-Tseng Chen, Jan W. Drijfhout et al. · The Journal of Experimental Medicine · 1998 · 725 citations · Full text
Life Sciences, Immunology, Oncology +17